Lesley Cown
Internal Medicine · Macon, GANPI 1346264702
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $23,413 of the $36,242 with a category attached, or 64.6%. 52 manufacturers reported payments, led by Amgen at 34.8% of the total. Reporting peaked in 2021 at $13,585 and has fallen 94.8% since, to $708 in 2025. Among internal medicine clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 675 payments — averaging $53.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$13K
- Biohaven Pharmaceutical Holding Company Ltd.$8K
- Biohaven Pharmaceuticals, Inc.$7K
- AbbVie$1K
- Novo Nordisk$1K
- Lilly USA, LLC$766
- plus $6K from 46 others
What the payments were for
- Speaking & faculty fees$23,41365%
- Travel & lodging$1,0203%
- Food & beverage$11,80433%
- Education$60%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$14,060
- AIMOVIG$9,995
- Repatha$1,123
- KYPHON Balloon Kyphoplasty$128
- EVENITY$125
- Prolia$125
- Kerendia$122
- XARELTO$114
- Synthroid$114
- FARXIGA$110
- MazorX - Renaissance$103
How this compares
$36,242 in reported general payments places this provider in the 95th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 147 | $212,925 |
| MounjaroTirzepatide | 154 | $181,116 |
| JardianceEmpagliflozin | 49 | $48,031 |
| EliquisApixaban | 78 | $40,416 |
| FarxigaDapagliflozin Propanediol | 17 | $27,346 |
| JanuviaSitagliptin Phosphate | 24 | $24,262 |
| TrulicityDulaglutide | 15 | $22,504 |
| LinzessLinaclotide | 14 | $18,161 |
| MyrbetriqMirabegron | 12 | $13,367 |
| VascepaIcosapent Ethyl | 25 | $9,609 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 12 | $6,722 |
| SynthroidLevothyroxine Sodium | 64 | $6,219 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $5,651 |
| Rosuvastatin Calcium | 333 | $3,418 |
| Levothyroxine Sodium | 302 | $3,331 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,052 | $212,925147 claims |
| Lilly USA, LLCMounjaro, Trulicity | $766 | $203,621169 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $534 | $53,68261 claims |
| PfizerEliquis | $594 | $40,41678 claims |
| AstraZenecaFarxiga | $624 | $27,34617 claims |
| AbbVieLinzess, Synthroid | $1,336 | $24,38078 claims |
| MerckJanuvia | $238 | $24,26224 claims |
| Astellas Pharma US IncMyrbetriq | $144 | $13,36712 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $35 | $3,331302 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Macon
- Michael GibsonSmyrna$2.2M
- Eduard FatakhovAlpharetta$376K
- Tracey HenryAtlanta$305K
- Sharon TuckettVilla Rica$265K
- Ebon BourneMarietta$242K
- Jennifer WoehlerSavannah$207K
- Julian HutchinsGreensboro$201K
- Brian PearlmanDalton$199K
- Scott ParryAtlanta$162K
- Jennifer GilliganAtlanta$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.